PCT #3

PATENT FOUNDATION
UNIVERSITY OF VIRGINIA

Patent Department
University of Virginia Patent Foundation
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
Main (434) 924-2175
Direct (434) 243-6103
Fax (434) 924-2493
Email rodney@uvapf.org

Rodney L. Sparks, J.D., Ph.D.
Biotechnology Patent Counsel

May 5, 2005

VIA UVA CAMPUS MAIL:
Richard L. Guerrant
Dept. of Internal Med. - Infectious Diseases
UVA Box 801379

VIA AIR MAIL:
Gerly Anne de Castro Brito
Rua República do Líbano, 710 apt 1100 - Meireles
Fortaleza, CE 60160-140
BRAZIL

VIA US MAIL:
Nathan Thielman, MD, MPH
Assistant Professor of Medicine
Div. of Infectious Diseases & International Health
Box 3152, Room 0376HS
Duke University Medical Center
Durham, NC 27710

Aldo A.M. Lima
Rua Pinho Pessoa #1289
Apr. 1000, Aldeota
Fortaleza CE 60.000
BRAZIL

Re: U. S. Patent Application Serial No. 10/530,805 filed April 8, 2005
National Stage of PCT/US2003/032379 filed October 10, 2003
Title: Use of Stable Glutamine Derivatives to Improve Drug Absorption
Our Reference: Guerrant-Clinical (00826-03)

Dear Inventors:

We are pleased to inform you that the above-identified PCT National Stage application was filed in the US Patent and Trademark Office on April 8, 2005. We have enclosed a copy of this application, which includes amendments to the specification. Please review and keep for your records.

We also enclose, for the inventors to sign, an assignment document assigning the rights in the captioned patent application from the inventors to the University of Virginia. Please sign and date the Assignment **in the presence of a notary**, have the notary affix their seal, and return the notarized document to us at your earliest convenience. (If it would be more convenient for you, we have a notary public at our office that can witness your signature.) Please fill in your resident address below the signature line if that information is missing, or correct that information if there

PRIVILEGED & CONFIDENTIAL

is an error.

As you are aware, there are also three important duties of each applicant (i.e., inventor) for a United States Patent; namely, the duties to name the true inventors; to disclose material information; and to disclose the best mode for practicing the invention. Anyone involved in the preparation and prosecution of a patent application has a continuing duty to disclose to the Patent Office all information of which they are aware, which is "material" to the examination of the application. Information may be material where there is a substantial likelihood that a reasonable Examiner would consider important in deciding whether to allow the application to issue as a patent.

We will prepare and file an information disclosure statement listing any information provided by you, or that is known to us to be material to the examination of the application. In addition, we will supply the U. S. Patent Office with one copy of each of the documents listed on the information disclosure statement. This information disclosure statement should be filed in the Patent Office within three months from the filing date of the application, or before the first office action is mailed. Later submissions may require the payment of a fee.

Please advise us as soon as possible of any information believed to be material to the examination of this application. This information includes prior art patents or literature and may also include earlier sales or public use of the invention or items or processes related to the invention. We also request that if possible you provide us with hard copies of those references. Please call us if you have any questions about what type of information should be disclosed.

Please note, that it is not necessary for you to conduct any searches of the literature, and you are not required to provide references that are cumulative in nature. Simply provide us with copies of references that are currently known to you to be relevant to the patentability of the captioned application.

If you have any questions regarding this matter, please do not hesitate to contact me.

Sincerely,

Rodney L. Sparks

Rodney L. Sparks
Biotechnology Patent Counsel

RLS/sh
Enclosure

cc: Rob Capon (w/ enclosure - copy of application)
AlGlutamine, LLC

PRIVILEGED & CONFIDENTIAL

(EFS-Web 1390 (05-02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	
00826-03	
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US2003/032379	10 October 2003 (10.10.2003)	11 October 2002 (11.10.2002)

TITLE OF INVENTION: Use of Stable Glutamine Derivatives to Improve Drug Absorption

APPLICANT(S) FOR DO/EO/US: UNIVERSITY OF VIRGINIA PATENT FOUNDATION; GUERRANT, Richard L.; THIELMAN, Nathan M.; BRITO, Gerly Anne de Castro and LIMA, Aldo A. M.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. [X] The US has been elected (Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is attached hereto (required only if not communicated by the International Bureau).
   b. [ ] has been communicated by the International Bureau.
   c. [X] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. [ ] is attached hereto.
   b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are attached hereto (required only if not communicated by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [X] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A preliminary amendment.
14. [ ] An Application Data Sheet under 37 CFR 1.76.
15. [ ] A substitute specification.
16. [ ] A power of attorney and/or change of address letter.
17. [ ] A computer-readable form of the sequence listing in accordance with PCT Rule 13*ter*.2 and 37 CFR 1.821- 1.825.
18. [ ] A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. [X] Other items or information: Small Entity Statement, Post Card Receipt

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
	PCT/US2003/032379	00826-03

The following fees have been submitted	CALCULATIONS	PTO USE ONLY
21. [X] Basic national fee $300	$ 300.00	
22. [X] Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) ..... $100 All other situations $200	$ 100.00	
23. [X] Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority ..... $100 International Search Report prepared and provided to the Office ..... $400 All other situations $500	$ 100.00	
TOTAL OF 21, 22 and 23 =	$ 500.00	

[ ] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is **$250** for each additional 50 sheets of paper or fraction thereof.

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE	
34 - 100 =	-66 /50 =		x $250	$ 0.00

Surcharge of **$130.00** for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)). $ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	$
Total claims	61 - 20 =	41	x $ 50	$ 2,050.00
Independent claims	3 - 3 =	0	x $200	$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $360	$ 360.00
			TOTAL OF ABOVE CALCULATIONS =	$ 2,910.00
[X] Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				1,455.00
			SUBTOTAL =	$ 1,455.00
Processing fee of **$130.00** for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)). +				$ 0.00
			TOTAL NATIONAL FEE =	$ 1,455.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$ 0.00
			TOTAL FEES ENCLOSED =	$ 1,455.00
			Amount to be refunded:	$
			Amount to be charged:	$

a. [ ] A check in the amount of $ _____ to cover the above fees is enclosed.

b. [X] Please charge my Deposit Account No. 50-0423 in the amount of $ 1,455.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0423. A duplicate copy of this sheet is enclosed.

d. [ ] Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

Rodney L. Sparks
CORRESPONDENCE TO:
University of Virginia Patent Foundation
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
US

Rodney L. Sparks
SIGNATURE

Rodney L. Sparks
NAME

53,625
REGISTRATION NUMBER